Get the Stockscreener App
1.06
0.00%
0.00
After Hours:
1.04
-0.02
-1.89%
Outlook Therapeutics Inc stock is traded at $1.06, with a volume of 2.60M.
It is up +0.00% in the last 24 hours and up +24.53% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.06
Open:
$1.08
24h Volume:
2.60M
Relative Volume:
0.75
Market Cap:
$47.08M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.265
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
+9.14%
1M Performance:
+24.53%
6M Performance:
-13.11%
1Y Performance:
-80.15%
1-Day Range:
$1.04
$1.11
1-Week Range:
$0.928
$1.1899
52-Week Range:
$0.79
$6.98
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.06 | 47.08M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Can Outlook Therapeutics Inc. stock continue upward trendWeekly Profit Analysis & Weekly High Momentum Picks - newser.com
OTLK Receives Neutral Rating from HC Wainwright & Co. | OTLK Sto - GuruFocus
H.C. Wainwright maintains Neutral rating on Outlook Therapeutics stock - Investing.com India
Is Outlook Therapeutics Inc. (41ON) stock good for long term investing2025 EndofYear Setup & Technical Confirmation Alerts - newser.com
Outlook Therapeutics plans FDA BLA resubmission for wet AMD treatment By Investing.com - Investing.com Nigeria
What analysts say about Outlook Therapeutics Inc stockBlue Chip Stock Analysis & Discover Stocks Experts Are Watching - earlytimes.in
Outlook Therapeutics stock price target raised to $13 from $8 at Brookline Capital - Investing.com Nigeria
Outlook Therapeutics Completes FDA Meeting on ONS-5010 - TipRanks
Outlook Therapeutics Plans to Resubmit ONS-5010 Biologics License Application Before Year-End - MarketScreener
Outlook Therapeutics Stock: To Buy or Not? - StocksToTrade
Why Outlook Therapeutics Inc. (41ON) stock is favored by hedge fundsWeekly Investment Recap & Fast Entry Momentum Trade Alerts - newser.com
How to recover losses in Outlook Therapeutics Inc. stockTrade Exit Report & AI Powered Market Trend Analysis - newser.com
Outlook Therapeutics stock surges after productive FDA meeting By Investing.com - Investing.com Nigeria
Outlook Therapeutics stock surges after productive FDA meeting - Investing.com India
Can Outlook Therapeutics Inc. rally from current levelsTrade Analysis Report & Momentum Based Trading Ideas - newser.com
What is the fair value of Outlook Therapeutics Inc. stock nowGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
How Outlook Therapeutics Inc. (41ON) stock moves in volatile trading sessions - newser.com
Outlook Therapeutics (OTLK) Engages in Constructive Talks with F - GuruFocus
Outlook Therapeutics (OTLK) Aims for BLA Resubmission by Year-En - GuruFocus
Outlook Therapeutics provides update on Type A Meeting with FDA - MarketScreener
Is Outlook Therapeutics Inc. (41ON) stock attractive for growth fundsOptions Play & Verified Swing Trading Watchlist - newser.com
Outlook Therapeutics plans FDA BLA resubmission for wet AMD treatment - Investing.com India
Outlook Therapeutics Provides Update On Type A Meeting With FDA - TradingView
Outlook Therapeutics Provides Update on Type A Meeting with FDA - GlobeNewswire
How Outlook Therapeutics Inc. (41ON) stock expands through international marketsJuly 2025 Outlook & Real-Time Stock Price Movement Reports - newser.com
Outlook Therapeutics, Inc. Announces Type A Meeting with the U.S. Food and Drug Administration Resubmission for Ons-5010 - MarketScreener
Market reaction to Outlook Therapeutics Inc.’s recent newsJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
What drives Outlook Therapeutics Inc 41ON stock priceFundamental Stock Analysis & Easy Tools to Analyze Your Investment Risk - earlytimes.in
How Outlook Therapeutics Inc. stock performs in interest rate cyclesJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
OTLK: Ascendiant Capital Lowers Price Target While Maintaining B - GuruFocus
Outlook Therapeutics, Inc.(NasdaqCM: OTLK) dropped from S&P Global BMI Index - MarketScreener
IPO Launch: What is RIBBR’s valuation compared to sectorWall Street Watch & Pattern Based Trade Signal System - khodrobank.com
Exit Recap: Is Outlook Therapeutics Inc. stock trending bullishEarnings Miss & Capital Efficient Trading Techniques - khodrobank.com
What data driven models say about Outlook Therapeutics Inc.’s future2025 Top Decliners & Reliable Price Breakout Alerts - newser.com
Sentiment Watch: Is Outlook Therapeutics Inc. showing insider buying2025 EndofYear Setup & Short-Term High Return Strategies - خودرو بانک
Performance Recap: Is Outlook Therapeutics Inc a top pick in the sector2025 Valuation Update & Weekly Watchlist for Consistent Profits - خودرو بانک
Applying sector rotation models to Outlook Therapeutics Inc.Take Profit & Verified Momentum Watchlists - newser.com
Short interest data insights for Outlook Therapeutics Inc.Long Setup & Advanced Technical Analysis Signals - newser.com
Published on: 2025-09-19 03:10:54 - خودرو بانک
Breakout Move: Is Outlook Therapeutics Inc forming a bullish divergenceLayoff News & Free Accurate Trade Setup Notifications - خودرو بانک
Largest borrow rate increases among liquid names - TipRanks
Bull Bear: Does Outlook Therapeutics Inc have consistent dividend growthProduct Launch & Weekly Stock Breakout Alerts - خودرو بانک
Growth Recap: Can Outlook Therapeutics Inc. navigate macro headwindsBear Alert & Real-Time Price Movement Reports - خودرو بانک
Aug Summary: Does Outlook Therapeutics Inc have strong EBITDA margins2025 Trading Volume Trends & Weekly High Return Forecasts - خودرو بانک
Movement Recap: Should you buy the dip on Outlook Therapeutics IncTrade Ideas & Weekly Top Gainers Alerts - خودرو بانک
Is Senseonics Holdings Inc forming bullish engulfing patternsPortfolio Profit Report & Fast Gaining Stock Reports - خودرو بانک
AI Stocks: How does Outlook Therapeutics Inc perform in inflationary periodsTrade Entry Report & Fast Momentum Stock Entry Tips - خودرو بانک
VIX Spike: Is Outlook Therapeutics Inc a top pick in the sectorJuly 2025 WrapUp & Capital Efficiency Focused Strategies - خودرو بانک
Sentiment Watch: Is Outlook Therapeutics Inc in a long term uptrend2025 Volume Leaders & High Yield Equity Trading Tips - خودرو بانک
Dip Buying: Is Outlook Therapeutics Inc forming a bullish divergenceWeekly Gains Report & Verified Entry Point Detection - خودرو بانک
Aug EndMonth: Will Outlook Therapeutics Inc benefit from government policySwing Trade & Low Risk Entry Point Guides - خودرو بانک
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):